NCT06511908
- Conditions
- Behavior, Behavioral Symptoms, Depression, +12 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Clinical trial condition
Molecular Mechanisms of Pharmacological Action
Explore clinical trials studying Molecular Mechanisms of Pharmacological Action. Study availability and eligibility vary by location and protocol.
18 public trials
5 recruiting studies
Molecular Mechanisms of Pharmacological Action trial results
NCT06462196
- Conditions
- Analgesics, Anesthetics, Anesthetics, Dissociative, +27 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
NCT06535568
- Conditions
- Acute Coronary Syndrome, Antineoplastic Agents, Arterial Occlusive Diseases, +23 more
- Locations
-
- IRCCS Auxologico Milano Milan, MI, Italy
NCT04289142
- Conditions
- Analgesics, Analgesics, Non-Narcotic, Central Nervous System Depressants, +16 more
- Locations
-
- Royal Columbian Hospital Vancouver, British Columbia, Canada
- St. Paul's Hospital Vancouver, British Columbia, Canada
- London Health Sciences London, Ontario, Canada
- Sunnybrook Health Sciences Centre Toronto, Ontario, Canada
NCT05465031
- Conditions
- Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Antihypertensive Agents, +24 more
- Locations
-
- Regional Cancer Centre in Opole Opole, Opole Voivodeship, Poland
- Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch Gliwice, Silesian Voivodeship, Poland
- Silesian Center for Heart Diseases Zabrze, Silesian Voivodeship, Poland
- Holy Cross Cancer Centre, Cardio-Oncology Division Kielce, Świętokrzyskie Voivodeship, Poland
Active, not recruiting
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
NCT04572451
- Conditions
- Antineoplastic Agents, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, +15 more
- Locations
-
- University of Chicago Medical Center Chicago, Illinois, United States
- UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
Active, not recruiting
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463
- Conditions
- Acetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents, +7 more
- Locations
-
- Merz Investigative Site Lyon, France
- Merz Investigative Site Munich, Bavaria, Germany
- Merz Investigative Site Blankenfelde-Mahlow, Brandenburg, Germany
- Merz Investigative Site Potsdam, Brandenburg, Germany
Active, not recruiting
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193
- Conditions
- Acetylcholine Release Inhibitors, Botulinum Toxins, Type A, Cholinergic Agents, +7 more
- Locations
-
- Merz Investigative Site Scottsdale, Arizona, United States
- Merz Investigative Site Encino, California, United States
- Merz Investigative Site Los Angeles, California, United States
- Merz Investigative Site Redondo Beach, California, United States
NCT03646292
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Digestive System Disease, +19 more
- Locations
-
- Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea Seoul, South Korea
NCT05657860
- Conditions
- Aberrant Motor Behavior in Dementia, Abnormalities, Multiple, Aggression, +34 more
- Locations
-
- Maimonides Medical Center Brooklyn, New York, United States